Jim Chanos - Likes Gilead, Still Short Valeant

Valeant drugs aren't helping the industry save money, he tells CNBC

Author's Avatar
Dec 18, 2015
Article's Main Image


Jim Chanos (Trades, Portfolio), president of Kynikos Associates, dissects Valeant (VRX, Financial), a company accused of non-standard financial relations with it a pharmaceutical provider by a short-seller earlier this year. He also asks whether raising prices by up to a thousand percent on acquired drugs will "move the needle" in health care costs for society, or just charge people more money who don't realize they're being gouged.